Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The evolution of beta2-agonists.

M R Sears1

  • 1McMaster University, Firestone Institute for Respiratory Health, St Joseph's Hospital, Hamilton, Ontario, Canada. searsm@mcmaster.ca

Respiratory Medicine
|September 6, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The influence of maternal and infant nutrition on cardiometabolic traits: novel findings and future research directions from four Canadian birth cohort studies.

The Proceedings of the Nutrition Society·2019
Same author

Impact of maternal pre-pregnancy overweight on infant overweight at 1 year of age: associations and sex-specific differences.

Pediatric obesity·2018
Same author

Human milk oligosaccharide profiles and food sensitization among infants in the CHILD Study.

Allergy·2018
Same author

Patterns of allergic sensitization and atopic dermatitis from 1 to 3 years: Effects on allergic diseases.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2017
Same author

Adiponectin, leptin and insulin in breast milk: associations with maternal characteristics and infant body composition in the first year of life.

International journal of obesity (2005)·2017
Same author

Infant gut immunity: a preliminary study of IgA associations with breastfeeding.

Journal of developmental origins of health and disease·2015
Same journal

Adults with Congenital Lung Malformations: A Descriptive Analysis of an Underexplored Population.

Respiratory medicine·2026
Same journal

Risk Factors and Microbiological Characteristics of Ventilator-Associated Pneumonia in a Tunisian Intensive Care Unit During the COVID-19 Pandemic.

Respiratory medicine·2026
Same journal

Impact of Therapeutic Hypothermia on Oxygen Demand and Respiratory Function in Post-Cardiac Arrest Patients: A Retrospective Cohort Study.

Respiratory medicine·2026
Same journal

The longitudinal decrease in exercise tolerance and disease progression in mild-to-moderate COPD.

Respiratory medicine·2026
Same journal

The implications of adopting the race-neutral spirometry equations in the detection of airway obstruction in Chilean children with asthma.

Respiratory medicine·2026
Same journal

Long-term outcomes of home mechanical ventilation in Duchenne Muscular Dystrophy - an observational study.

Respiratory medicine·2026
See all related articles

Short-acting beta2-agonists are crucial for asthma emergencies and exercise-induced bronchoconstriction. However, long-acting beta2-agonists like salmeterol and formoterol offer sustained relief and improved quality of life when used with inhaled corticosteroids.

Area of Science:

  • Pharmacology
  • Respiratory Medicine
  • Clinical Therapeutics

Background:

  • Beta-agonists are mainstays in asthma treatment, despite historical safety concerns.
  • Short-acting beta2-agonists (SABAs) are vital for exercise-induced bronchoconstriction and acute asthma attacks.
  • Regular SABA use offers limited benefit and may worsen asthma severity.

Purpose of the Study:

  • To review the role and safety of beta-agonists in asthma management.
  • To compare the benefits of short-acting versus long-acting beta2-agonists.
  • To evaluate the efficacy of long-acting beta2-agonists when combined with inhaled corticosteroids.

Main Methods:

  • Review of existing literature on beta-agonist use in asthma.
  • Analysis of clinical trial data comparing different beta-agonist formulations.

Related Experiment Videos

  • Assessment of safety profiles and adverse event data.

    • Main Results:

    • Long-acting beta2-agonists (LABAs), such as salmeterol and formoterol, provide prolonged bronchodilation and symptom control.
    • LABAs improve sleep quality and reduce the need for SABAs.
    • Combination therapy with LABAs and inhaled corticosteroids enhances lung function more than increased steroid dosage alone.
    • Formoterol's rapid onset allows for potential as-needed bronchodilator therapy.

    Conclusions:

    • LABAs represent a significant advancement in asthma management, offering improved symptom control and quality of life.
    • When used with inhaled corticosteroids, LABAs are well-tolerated and effective.
    • Formoterol holds promise for both maintenance and as-needed treatment strategies in asthma.